Sarepta Acquires Investigational Gene Therapy for LGMD2A

Sarepta Acquires Investigational Gene Therapy for LGMD2A

301832

Sarepta Acquires Investigational Gene Therapy for LGMD2A

Sarepta Therapeutics has executed an exclusive license agreement for a gene therapy candidate that aims to treat limb-girdle muscular dystrophy type 2A (LGMD2A), the company announced. The investigational therapy, called calpain 3 or CAPN-3, was developed at the Abigail Wexner Research Institute at Nationwide Children’s Hospital, in Columbus, Ohio. The deal followed a number of successful preclinical and safety studies led by Zarife Sahenk, MD, PhD, an attending neurologist at the hospital. Recommended Reading March…

You must be logged in to read/download the full post.